Evidence map›Paper›PMID 41739919›Full record

ArticleScience advances2026

Preclinical development of a well-defined semisynthetic glycoconjugate vaccine against

Wei Han, Chunjun Qin, Wei Tong, Kexin Yang, Xianbin Tian, Jing-Ren Zhang, Jiankai Liu, Peter H Seeberger, Jing Hu, Jian Yin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wei HanSchool of Biotechnology and Key Laboratory of Carbohydrate Chemistry and Biotechnology of Ministry of Education, Jiangnan University, Wuxi 214122, P.R. China.ORCID 0009-0005-1518-9920
Chunjun QinSchool of Biotechnology and Key Laboratory of Carbohydrate Chemistry and Biotechnology of Ministry of Education, Jiangnan University, Wuxi 214122, P.R. China.ORCID 0009-0004-8974-5507
Wei TongBeijing Minhai Biotechnology Co., Ltd., Beijing 102600, P.R. China.
Kexin YangSchool of Biotechnology and Key Laboratory of Carbohydrate Chemistry and Biotechnology of Ministry of Education, Jiangnan University, Wuxi 214122, P.R. China.ORCID 0009-0004-7073-607X
Xianbin TianCenter for Infectious Biology, School of Basic Medical Sciences, Tsinghua University, Beijing 100084, P.R. China.ORCID 0000-0001-7329-639X
Jing-Ren ZhangCenter for Infectious Biology, School of Basic Medical Sciences, Tsinghua University, Beijing 100084, P.R. China.ORCID 0000-0003-4973-4243
Jiankai LiuBeijing Minhai Biotechnology Co., Ltd., Beijing 102600, P.R. China.ORCID 0009-0002-1495-7113
Peter H SeebergerBiomolecular Systems Department, Max Planck Institute of Colloids and Interfaces, Potsdam 14476, Germany.ORCID 0000-0003-3394-8466
Jing HuInnovation Center for Vaccine Engineering, Jiangnan University, Wuxi 214122, P.R. China.ORCID 0000-0003-3288-7067
Jian YinSchool of Biotechnology and Key Laboratory of Carbohydrate Chemistry and Biotechnology of Ministry of Education, Jiangnan University, Wuxi 214122, P.R. China.ORCID 0000-0002-2284-1666

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccines are the most effective method for preventing bacterial infections. Identification of the best hapten is an essential step in the development of third-generation

Identifiers

PMID41739919
PMCPMC12935054

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.